Covid-19 roundup: Mod­er­na's stock plunges af­ter low­er sales fore­cast is re­vealed; Re­gen­eron sees $804M in Q3 mon­o­clon­al an­ti­body sales

Mod­er­na’s stock $MR­NA plunged more than 14% in pre­mar­ket trad­ing on Thurs­day af­ter the biotech cut its end-of-year vac­cine sales fore­cast.

Ac­cord­ing to its Q3 re­sults, Mod­er­na now plans on de­liv­er­ing be­tween 700 mil­lion and 800 mil­lion dos­es of its Covid-19 vac­cine by the end of the year, down from its Q2 pro­jec­tion of 800 mil­lion to 1 bil­lion dos­es. Some dos­es ex­pect­ed for de­liv­ery this year have been shift­ed to next year, Mod­er­na said, as it pri­or­i­tizes de­liv­ery to low-in­come coun­tries through CO­V­AX and the African Union.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER